Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma

Hyunji Lee, Minhee Kim, Seon Hwan Kim, Quangdon Tran, Gyeyeong Kong, Chaeyeong Kim, So Hee Kwon, Jisoo Park, Jin Bong Park, Sungjin Park, Jongsun Park

Research output: Contribution to journalArticlepeer-review

Abstract

Alpha-Methylacyl-CoA racemase (AMACR), which was initially discovered as a prostate cancer marker, is critical for the chiral inversion mechanism of branched-chain fatty acids. However, the function of AMACR in brain tumors has not been investigated. In this study, AMACR appeared to be involved in glioblastoma. The protein and mRNA levels of AMACR were highly elevated in glioblastoma. Downregulation of AMACR inhibited cell proliferation. Comprehensive analysis of the public REMBRANDT GBM dataset also confirmed that the level of AMACR expression was correlated with the clinical prognosis of glioma patients. In summary, these findings indicate that AMACR expression is increased in a glioblastoma cell line and glioma patients, suggesting that AMACR might be a potential diagnostic marker and therapeutic target for cancer, including glioma.

Original languageEnglish
Article number550673
JournalFrontiers in Oncology
Volume10
DOIs
Publication statusPublished - 2020 Oct 13

Bibliographical note

Funding Information:
This work was financially supported by a research fund from Chungnam National University (grant to JoP), by Chungnam, National University Hospital Research Fund, 2012 (S-HK), by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2015R1A2A2A01003597, NRF-2016K1A3A1A08 953546), and by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0660).

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma'. Together they form a unique fingerprint.

Cite this